Biswas, S., Srivastava, Y., Hamadttu, A. (2026). Comparative real-world outcomes of durvalumab plus gemcitabine/cisplatin versus pembrolizumab plus gemcitabine/cisplatin as first-line therapy for advanced biliary tract cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.133